{"id":58731,"date":"2026-03-04T13:24:21","date_gmt":"2026-03-04T05:24:21","guid":{"rendered":"https:\/\/flcube.com\/?p=58731"},"modified":"2026-03-04T13:24:21","modified_gmt":"2026-03-04T05:24:21","slug":"leman-biotech-raises-rmb-200m-series-a-advances-ultra-low-dose-metabolically-armored-car-t","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58731","title":{"rendered":"Leman Biotech Raises RMB 200M Series A+ \u2013 Advances Ultra\u2011Low\u2011Dose Metabolically Armored CAR\u2011T"},"content":{"rendered":"\n<p><strong>Leman Biotech Co., Ltd.<\/strong> announced the completion of a <strong>Series A+ financing round<\/strong> totaling <strong>nearly RMB\u202f200\u202fmillion (~\u202fUSD\u202f29\u202fmillion)<\/strong>. The round was <strong>co\u2011led by Yuecai Holdings and XtalPi<\/strong>, with participation from <strong>Mony Valley, Tailong Capital<\/strong>, and individual investors. <strong>Existing shareholder Fuho Capital<\/strong> increased its stake. The proceeds will advance <strong>registrational Phase I trials<\/strong> of <strong>ultra\u2011low\u2011dose metabolically armored CAR\u2011T cell therapy<\/strong> and <strong>automated manufacturing scale\u2011up<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financing-overview\">Financing Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Leman Biotech Co., Ltd.<\/td><\/tr><tr><td><strong>Round<\/strong><\/td><td>Series A+<\/td><\/tr><tr><td><strong>Amount<\/strong><\/td><td><strong>~\u202fRMB\u202f200\u202fmillion (~\u202fUSD\u202f29\u202fmillion)<\/strong><\/td><\/tr><tr><td><strong>Co\u2011Leads<\/strong><\/td><td>Yuecai Holdings, XtalPi<\/td><\/tr><tr><td><strong>New Investors<\/strong><\/td><td>Mony Valley, Tailong Capital, individual financial investors<\/td><\/tr><tr><td><strong>Existing Investor (Increased)<\/strong><\/td><td>Fuho Capital<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>Phase I registrational study; automated manufacturing; solid tumor translation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-metabolically-armored-car-t\">Technology Platform \u2013 Metabolically Armored CAR\u2011T<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Innovation<\/th><th>Clinical Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Ultra\u2011Low\u2011Dose<\/strong><\/td><td>Reduced cell numbers required<\/td><td>Lower manufacturing cost; reduced cytokine release syndrome (CRS) risk<\/td><\/tr><tr><td><strong>Metabolic Armor<\/strong><\/td><td>Genetic\/enzymatic modifications enhancing T\u2011cell metabolic fitness<\/td><td>Improved persistence in hostile tumor microenvironment<\/td><\/tr><tr><td><strong>Solid Tumor Targeting<\/strong><\/td><td>Enhanced metabolic resilience<\/td><td>Addresses hypoxia, nutrient deprivation, immunosuppression in solid tumors<\/td><\/tr><tr><td><strong>Automated Manufacturing<\/strong><\/td><td>Closed\u2011system, scalable production<\/td><td>Cost reduction; batch consistency; global supply capability<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CAR\u2011T Cost Revolution:<\/strong> <strong>Ultra\u2011low\u2011dose administration<\/strong>\u2014enabled by <strong>metabolic armor technology<\/strong>\u2014could <strong>reduce manufacturing costs 50\u201170%<\/strong> vs. standard CAR\u2011T, addressing the <strong>primary barrier to global access<\/strong> (current CAR\u2011T priced at $300K\u2011$500K).<\/li>\n\n\n\n<li><strong>Solid Tumor Breakthrough:<\/strong> Traditional CAR\u2011T fails in solid tumors due to <strong>poor persistence<\/strong>; Leman&#8217;s <strong>metabolic engineering<\/strong> enables <strong>T\u2011cell survival in hypoxic, nutrient\u2011deprived microenvironments<\/strong>, potentially <strong>unlocking lung, gastric, and liver cancer indications<\/strong>.<\/li>\n\n\n\n<li><strong>XtalPi AI Synergy:<\/strong> <strong>XtalPi&#8217;s co\u2011lead investment<\/strong> suggests <strong>AI\u2011driven discovery collaboration<\/strong>\u2014potentially applying <strong>machine learning to metabolic pathway optimization<\/strong> and <strong>patient selection biomarkers<\/strong>.<\/li>\n\n\n\n<li><strong>Registrational Phase I:<\/strong> The <strong>&#8220;registrational&#8221; designation<\/strong> implies <strong>pivotal trial readiness<\/strong> and <strong>accelerated regulatory pathway<\/strong>, potentially enabling <strong>China approval within 2\u20113 years<\/strong> if efficacy and safety are confirmed.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Global CAR\u2011T Market<\/strong><\/td><td>~\u202f$8\u202fbillion (2024); dominated by hematologic malignancies; solid tumor expansion is next frontier<\/td><\/tr><tr><td><strong>Manufacturing Cost Crisis<\/strong><\/td><td>Autologous CAR\u2011T requires 3\u20114 weeks production; ultra\u2011low\u2011dose + automated manufacturing could democratize access<\/td><\/tr><tr><td><strong>China Cell Therapy Leadership<\/strong><\/td><td>NMPA has approved 5+ domestic CAR\u2011T products; metabolic engineering represents next\u2011generation innovation<\/td><\/tr><tr><td><strong>Metabolic Modification Trend<\/strong><\/td><td>Armoring T\u2011cells against tumor microenvironment hostility is emerging as key differentiator (e.g., CRISPR\u2011edited metabolic enzymes)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase I enrollment, metabolic armor mechanism validation, and automated manufacturing scale\u2011up. Actual results may differ due to risks including solid tumor microenvironment complexity, competitive allogeneic CAR\u2011T development, and long\u2011term persistence data requirements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Leman Biotech Co., Ltd. announced the completion of a Series A+ financing round totaling nearly&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58733,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,21,77,2038],"class_list":["post-58731","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-car-t","tag-cell-therapy","tag-leman-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Leman Biotech Raises RMB 200M Series A+ \u2013 Advances Ultra\u2011Low\u2011Dose Metabolically Armored CAR\u2011T - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Leman Biotech Co., Ltd. announced the completion of a Series A+ financing round totaling nearly RMB\u202f200\u202fmillion (~\u202fUSD\u202f29\u202fmillion). The round was co\u2011led by Yuecai Holdings and XtalPi, with participation from Mony Valley, Tailong Capital, and individual investors. Existing shareholder Fuho Capital increased its stake. The proceeds will advance registrational Phase I trials of ultra\u2011low\u2011dose metabolically armored CAR\u2011T cell therapy and automated manufacturing scale\u2011up.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58731\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leman Biotech Raises RMB 200M Series A+ \u2013 Advances Ultra\u2011Low\u2011Dose Metabolically Armored CAR\u2011T\" \/>\n<meta property=\"og:description\" content=\"Leman Biotech Co., Ltd. announced the completion of a Series A+ financing round totaling nearly RMB\u202f200\u202fmillion (~\u202fUSD\u202f29\u202fmillion). The round was co\u2011led by Yuecai Holdings and XtalPi, with participation from Mony Valley, Tailong Capital, and individual investors. Existing shareholder Fuho Capital increased its stake. The proceeds will advance registrational Phase I trials of ultra\u2011low\u2011dose metabolically armored CAR\u2011T cell therapy and automated manufacturing scale\u2011up.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58731\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-04T05:24:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0403.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58731#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58731\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Leman Biotech Raises RMB 200M Series A+ \u2013 Advances Ultra\u2011Low\u2011Dose Metabolically Armored CAR\u2011T\",\"datePublished\":\"2026-03-04T05:24:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58731\"},\"wordCount\":447,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58731#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0403.webp\",\"keywords\":[\"Cancer\",\"CAR-T\",\"Cell-therapy\",\"Leman Biotech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58731#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58731\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58731\",\"name\":\"Leman Biotech Raises RMB 200M Series A+ \u2013 Advances Ultra\u2011Low\u2011Dose Metabolically Armored CAR\u2011T - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58731#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58731#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0403.webp\",\"datePublished\":\"2026-03-04T05:24:21+00:00\",\"description\":\"Leman Biotech Co., Ltd. announced the completion of a Series A+ financing round totaling nearly RMB\u202f200\u202fmillion (~\u202fUSD\u202f29\u202fmillion). The round was co\u2011led by Yuecai Holdings and XtalPi, with participation from Mony Valley, Tailong Capital, and individual investors. Existing shareholder Fuho Capital increased its stake. The proceeds will advance registrational Phase I trials of ultra\u2011low\u2011dose metabolically armored CAR\u2011T cell therapy and automated manufacturing scale\u2011up.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58731#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58731\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58731#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0403.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0403.webp\",\"width\":1080,\"height\":608,\"caption\":\"Leman Biotech Raises RMB 200M Series A+ \u2013 Advances Ultra\u2011Low\u2011Dose Metabolically Armored CAR\u2011T\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58731#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leman Biotech Raises RMB 200M Series A+ \u2013 Advances Ultra\u2011Low\u2011Dose Metabolically Armored CAR\u2011T\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Leman Biotech Raises RMB 200M Series A+ \u2013 Advances Ultra\u2011Low\u2011Dose Metabolically Armored CAR\u2011T - Insight, China&#039;s Pharmaceutical Industry","description":"Leman Biotech Co., Ltd. announced the completion of a Series A+ financing round totaling nearly RMB\u202f200\u202fmillion (~\u202fUSD\u202f29\u202fmillion). The round was co\u2011led by Yuecai Holdings and XtalPi, with participation from Mony Valley, Tailong Capital, and individual investors. Existing shareholder Fuho Capital increased its stake. The proceeds will advance registrational Phase I trials of ultra\u2011low\u2011dose metabolically armored CAR\u2011T cell therapy and automated manufacturing scale\u2011up.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58731","og_locale":"en_US","og_type":"article","og_title":"Leman Biotech Raises RMB 200M Series A+ \u2013 Advances Ultra\u2011Low\u2011Dose Metabolically Armored CAR\u2011T","og_description":"Leman Biotech Co., Ltd. announced the completion of a Series A+ financing round totaling nearly RMB\u202f200\u202fmillion (~\u202fUSD\u202f29\u202fmillion). The round was co\u2011led by Yuecai Holdings and XtalPi, with participation from Mony Valley, Tailong Capital, and individual investors. Existing shareholder Fuho Capital increased its stake. The proceeds will advance registrational Phase I trials of ultra\u2011low\u2011dose metabolically armored CAR\u2011T cell therapy and automated manufacturing scale\u2011up.","og_url":"https:\/\/flcube.com\/?p=58731","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-04T05:24:21+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0403.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58731#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58731"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Leman Biotech Raises RMB 200M Series A+ \u2013 Advances Ultra\u2011Low\u2011Dose Metabolically Armored CAR\u2011T","datePublished":"2026-03-04T05:24:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58731"},"wordCount":447,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58731#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0403.webp","keywords":["Cancer","CAR-T","Cell-therapy","Leman Biotech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58731#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58731","url":"https:\/\/flcube.com\/?p=58731","name":"Leman Biotech Raises RMB 200M Series A+ \u2013 Advances Ultra\u2011Low\u2011Dose Metabolically Armored CAR\u2011T - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58731#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58731#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0403.webp","datePublished":"2026-03-04T05:24:21+00:00","description":"Leman Biotech Co., Ltd. announced the completion of a Series A+ financing round totaling nearly RMB\u202f200\u202fmillion (~\u202fUSD\u202f29\u202fmillion). The round was co\u2011led by Yuecai Holdings and XtalPi, with participation from Mony Valley, Tailong Capital, and individual investors. Existing shareholder Fuho Capital increased its stake. The proceeds will advance registrational Phase I trials of ultra\u2011low\u2011dose metabolically armored CAR\u2011T cell therapy and automated manufacturing scale\u2011up.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58731#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58731"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58731#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0403.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0403.webp","width":1080,"height":608,"caption":"Leman Biotech Raises RMB 200M Series A+ \u2013 Advances Ultra\u2011Low\u2011Dose Metabolically Armored CAR\u2011T"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58731#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Leman Biotech Raises RMB 200M Series A+ \u2013 Advances Ultra\u2011Low\u2011Dose Metabolically Armored CAR\u2011T"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0403.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58731"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58731\/revisions"}],"predecessor-version":[{"id":58734,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58731\/revisions\/58734"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58733"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}